The tumor suppressor BRCA2 is essential for homologous recombination, replication fork 2 stability and DNA interstrand crosslink (ICL) repair in vertebrates. We show that a 3 functionally uncharacterized protein, HSF2BP, is involved in a novel, direct and highly 4 evolutionarily conserved interaction with BRCA2. Although HSF2BP was previously described 5 as testis-specific, we find it is expressed in mouse ES cells, in human cancer cell lines, and in 6 tumor samples. Elevated levels of HSF2BP sensitize human cells to ICL-inducing agents 7 (mitomycin C and cisplatin) and PARP inhibitors, resulting in a phenotype characteristic of 8 cells from Fanconi anemia (FA) patients. We biochemically recapitulate the suppression of 9 ICL repair and establish that excess HSF2BP specifically compromises homologous 10 recombination by preventing BRCA2 and RAD51 loading at the ICL. As increased ectopic 11 expression of HSF2BP occurs naturally, we suggest that it can be considered as a causative 12 agent in FA and a source of cancer-promoting genomic instability. 13 14 2
Introduction 1 Breast cancer associated protein 2 (BRCA2) has been the subject of intense research 2 because of its role as a tumor suppressor and the mediator of homologous recombination 3 (HR) (Prakash et al., 2015; Roy et al., 2012; Zelensky et al., 2014) . Yet important questions 4 concerning the roles of specific domains in BRCA2, such as its most conserved region (the 5 DNA-binding domain) or internally disordered regions, relative importance of distinct 6 activities of the protein, etc. remain open. A major breakthrough in understanding the 7 molecular function of BRCA2 came from the identification of RAD51 as an interaction 8 partner (Sharan et al., 1997) . Interaction of BRCA2 with other proteins, known (Martinez et 9 al., 2015 ) and yet undiscovered, will help address some of the open questions. 10 During DNA interstrand crosslink (ICL) repair several substrates for HR arise, beginning with 11 maintenance and rearrangement of the replication fork, and up to accurate repair of the 12 DNA double-strand break (DSB) that is created after nucleolytic disengagement of the 13 crosslinked strands. Recognition of the lesion, damage response signaling and coordination 14 of the multiple distinct enzymatic reactions that need to happen to restore genetic 15 information, is performed by a large and still growing group of proteins from the Fanconi 16 anemia (FA) pathway, which as of now comprises of 22 proteins, designated FANCA-FANCW 17 (Auerbach, 2009; Inano et al., 2017; Knies et al., 2017; Kottemann and Smogorzewska, 18 2013). 19 The functional connection between HR and FA has been demonstrated in numerous studies, , 2008; 2010) . However, these are suggestions mostly based on co-immunoprecipitation 25 and co-localization to DNA damage-induced focal accumulations of proteins, with evidence 26 for direct binding limited to yeast two-hybrid analyses. Given the complexity and the 27 properties of the proteins involved, indirect interaction via DNA, chromatin or intermediary 28 proteins may explain the reported co-occurrence of FA and HR proteins in foci and 29 precipitates. On the other hand, the direct interactions that do take place and are 30 3 responsible for the coordination between early FA factors and HR may be dynamic, low 1 affinity, dependent on post-translational modifications, and thus evade discovery. The 2 FANCD2-FANCI complex was recently demonstrated to directly bind to RAD51 using purified 3 proteins (Sato et al., 2016) . Characterization of other such interactions would help to 4 understand the engagement between upstream FA and downstream HR machineries and 5 interpret the existing data. 6 In this report we describe a novel, direct and highly evolutionarily conserved interaction of 7 BRCA2 with HSF2BP, a protein previously only identified in testis and not characterized 8 functionally. We show that the interaction between BRCA2 and HSF2BP ectopically 9 produced in human cancer cells specifically disrupts HR in the context of ICL repair and 10 sensitizes cells to poly (ADP-ribose) polymerase inhibitors (PARPi), but does not affect all 11 BRCA2-dependent HR reactions, thus creating a setting in which BRCA2 functions are 12 separated. 13 
Results

14
HSF2BP is a member of the BRCA complex in mES cells 15 We previously described efficient immunoprecipitation of BRCA2-GFP and most of the 16 known BRCA2-interacting proteins from Brca2 GFP/GFP knock-in mouse embryonic stem (mES) 17 cells (Reuter et al., 2014) , and the phenomenon of BRCA2 degradation induced by mild 18 hyperthermia (Krawczyk et al., 2011) . With these at hand we performed quantitative SILAC- 19 based mass spectrometry experiments and identified HSF2BP as one of the proteins whose 20 abundance in the BRCA2-GFP immunoprecipitate co-varies with that of BRCA2 upon 21 hyperthermia treatment [ Fig 1A] . HSF2BP was previously described as a testis-specific, heat 22 shock factor 2 (HSF2) binding protein (Yoshima et al., 1998) , and its association with BRCA2 23 or expression in tissues other than testis has not yet been reported. A reciprocal mass 24 spectrometry experiment -GFP immunoprecipitation from Hsf2bp GFP/+ knock-in mES cells 25 that we engineered -confirmed the interaction [Fig 1B] . As a control in these experiments 26 we used immunoprecipitation from Rad51ap1 GFP/GFP knock-in cells, to ensure the 27 interactions were not due to non-specific binding to a nuclear GFP-tagged low abundance 28 DNA repair proteins (Modesti et al., 2007) . The efficiency of BRCA2 immunoprecipitation via 29 HSF2BP-GFP was remarkably high, similar to direct BRCA2-GFP immunoprecipitation, which 1 is noteworthy as in our experience immunoprecipitation of large low abundance HR 2 proteins is not straightforward. Furthermore, HSF2BP co-precipitated with PALB2, the 3 partner and localizer of BRCA2 (Xia et al., 2006) from Palb2 GFP/GFP knock-in mES cells [ Fig 1C] . 4 HSF2BP-GFP in Hsf2bp GFP/+ cells was predominantly nuclear and localized to ionizing 5 radiation-induced foci readily detectable without pre-extraction [ Fig 1D] . The foci co-6 localized with DSB marker 53BP1, but were observed in a fraction of cells [ Fig 1E] , as 7 expected given that HR activity, and specifically BRCA2 expression in mES cells (Reuter et al., 8 2014) , is confined to S and G2 phases of cell cycle. We previously found using oblique 9 illumination microscopy and single particle tracking that endogenous GFP-tagged BRCA2 10 diffuses in oligomeric clusters that become immobilized upon induction of DNA damage 11 (Reuter et al., 2014) . The same technique was applied to monitor and quantify HSF2BP-GFP 12 diffusion in the nucleus, which revealed heterogeneous behavior very similar to that of 13 BRCA2-GFP, including ionizing radiation-induced immobilization [ Fig 1F] . Taken together, 14 the immunoprecipitation mass spectrometry, and microscopy data suggest that HSF2BP and 15 BRCA2 exist in a physiological complex in mES cells, which may be constitutive. 16 The interaction between HSF2BP and BRCA2 appears to be conserved, as in addition to the 17 interaction between the mouse proteins, we detected association between their human 18 orthologues [Fig1 G]. Furthermore, endogenous X. laevis BRCA2 interacted efficiently with 19 both recombinant X. laevis HSF2BP (xlHSF2BP) and recombinant human HSF2BP [Fig1 H]. 20 Most experiments described below were performed with the human proteins, and where 21 mouse (mHSF2BP) and human (hHSF2BP) proteins were tested alongside in human cells, the 22 observed effects were similar (see below). Thus HSF2BP-BRCA2 interaction is evolutionarily 23 conserved, which is remarkable given the evolutionary distance between the species and 24 indicates that the interaction is under strong selective pressure and thus functionally 25 important. 26 We initially identified mHSF2BP in mES cells, could readily detect HSF2BP transcripts by PCR in all human cancer cell lines we tested [ Fig S1A-D] , and cloned the full-length hHSF2BP 28 coding sequence (CDS) to produce the various expression constructs used in the study by 29 RT-PCR from RNA isolated from human U2OS cells, which are from osteosarcoma rather 30 5 than testis origin. By inspection of public RNA expression datasets (Harding et al., 2011; 1 Petryszak et al., 2016; Shin et al., 2011; Tang et al., 2017) , we found indications of high level 2 expression of HSF2BP -in addition to testis -in mouse embryonic ovaries and some human 3 cancer samples derived from brain, breast, ovarian and head and neck tumors [ Fig S1E] . We 4 tested three of the human cancer cell lines that had elevated HSF2BP expression levels 5 (MDA-MB-157 (breast), HCC1187 (breast) and ), and could detect HSF2BP in 6 all of them [ Fig 1I] . These findings indicate that HSF2BP promoter can be activated in cancer 7 cells of non-testicular origin. In conjunction with the BRCA2 interaction, this prompted us to 8 explore its possible effects on homologous recombination. 9 HSF2BP overproduction disrupts the FA pathway S2I]. The last observation argues against cytoplasmic sequestration as the mechanism, as 1 was previously proposed to explain the inhibitory effect of HSF2BP on transcription factor 2 BNC1 (Wu et al., 2013) . 3 To show that HSF2BP directly acts in the FA pathway of ICL repair, we took advantage of the 4 evolutionary conservation of the HSF2BP-BRCA2 interaction [ Fig 1H] and made use of the 5 Xenopus egg extract-based ICL repair system. This system allows the repair of a single, site-6 specific cisplatin interstrand crosslink situated on a plasmid in a replication-and FA 7 pathway-dependent manner (Knipscheer et al., 2012; 2009; Räschle et al., 2008) . Using 8 Xenopus egg extract, which does not contain endogenous xlHSF2BP at the level detectable 9 by immunoblotting, we replicated the crosslinked plasmid (pICL) in the presence or absence 10 of recombinant HSF2BP. Replication intermediates were isolated and repair efficiency was 11 determined by measuring the regeneration of a SapI recognition site that is blocked by the 12 ICL prior to repair. Addition of hHSF2BP almost completely abrogated ICL repair [ Fig 2F, S2J] . 13 Importantly, addition of xlHSF2BP inhibited ICL repair to the same extent [ Fig S2K] . These 14 data suggest that ICL sensitivity of HSF2BP overexpressing cells is due to inhibition of ICL 15 repair by the FA pathway. 16 Mapping the BRCA2-HSF2BP interaction 17 To identify the regions required for the interaction between BRCA2 and HSF2BP we 18 engineered a series of Flag-tagged BRCA2 fragment expression constructs and GFP-tagged 19 HSF2BP expression constructs [ Fig 3A-C] . For BRCA2, starting by dividing the protein into 20 three fragments (N-terminal, middle, and C-terminal) [Fig S3A] , we mapped the HSF2BP-21 binding domain (HBD) to the 68 amino acid region (BRCA2-F9, Gly2270-Thr2337 in hBRCA2) 22 located between the eighth BRC repeat (BRC8) and the DNA binding domain [ Fig 3C] . 23 Despite generally modest conservation of the region between BRC8 and the DNA binding 24 domain, the BRCA2-F9 HBD is highly conserved and contains amino acid motifs that are 25 perfectly conserved among vertebrate BRCA2 orthologues, including X. laevis [ Fig S3B] . Most of the GFP-fused truncated or internally deleted forms of HSF2BP we engineered were 1 expressed at much lower levels than the full-length protein in human cells, presumably due 2 to instability caused by misfolding [ Fig 3C, lanes 8-10] . However, we could establish that 3 deletions of the central and C-terminal parts of HSF2BP, which are predicted to adopt the 4 armadillo repeat folds (e.g. Phyre2 (Mezulis et al., 2015) ) abolished the interaction. Using 5 internal deletions and eventually a set of seven point mutants [ Fig S3C] , we established that 6 this region is required for interaction with BRCA2, and that a single amino acid change in 7 HSF2BP at position 200 from Arginine to Threonine (R200T) greatly reduces its ability to co-8 precipitate BRCA2 [ Fig 3C lanes 11-13] . Notably, this residue is fully conserved among 9 vertebrates. We could also establish that the N-terminal 92 amino acids, which are not 10 predicted to contain armadillo folds and show weak sequence similarity to coiled coil 11 regions, are not required for the interaction with BRCA2 [ Fig 3C lane 8] . 12 To establish whether HSF2BP-BRCA2 interaction is direct, we purified bacterially expressed 13 HSF2BP variants and BRCA2 fragments tagged with 6xHis or GST [ Fig 3D] that could be 14 cleaved off with TEV protease. Full-length HSF2BP was retained by GST-tagged BRCA2 F6 15 immobilized on glutathione sepharose beads, which demonstrated direct interaction 16 between BRCA2 and HSF2BP. Consistent with the immunoprecipitation results, purified 17 R200T mutant did not bind BRCA2-F6 efficiently [ Fig 3D] . Analytical gel filtration of HSF2BP 18 (wild-type or R200T) and BRCA2-F8, re-purified after cleaving off affinity tags, confirmed the 19 formation of a complex between the two proteins [ Fig 3E] . The hydrodynamic volume of 20 HSF2BP was several fold higher than expected for a globular monomeric protein of its size 21 (37.6 kDa), suggesting that HSF2BP exists in oligomeric and/or elongated form [ Fig S3D] . 22 To show that the interaction with BRCA2 is important for the inhibition of the FA pathway 23 by HSF2BP we monitored cisplatin ICL repair in Xenopus egg extract in the presence of wild 24 type or R200T mutant hHSF2BP. While addition of wildtype HSF2BP strongly reduced ICL 25 repair, addition of the R200T mutant protein showed comparable ICL repair efficiency to a 26 condition where no protein was added [ Fig 3F, S3E] . Consistent with this, overproduction of 27 HSF2BP R200T did not significantly sensitize U2OS cells to MMC [ Fig 3G] . This indicates that 28 the HSF2BP-BRCA2 interaction is required for the inhibitory effect of HSF2BP on ICL repair. 29 8 HSF2BP inhibits HR in the FA pathway 1 BRCA2 has a role in homologous recombination but also acts in the response to stalled 2 replication forks. HSF2BP could therefore inhibit ICL repair at various stages of the repair 3 process. Because ICLs are repaired synchronously in Xenopus egg extract we could 4 investigate which repair step is affected by HSF2BP addition. An early key event in cisplatin 5 ICL repair are the XPF-ERCC1-mediated nucleolytic incisions that unhook the ICL from one of 6 the strands. These incisions can be directly observed during ICL repair in egg extract by 7 replicating parentally labelled pICL [ Fig S4A] . Replication intermediates are linearized and 8 separated on denaturing agarose gels [ Fig S4B] . The parental strand first migrates as a large 9 X-shaped structure and during ICL unhooking it is converted to a linear molecule and arms 10 (Klein Douwel et al., 2014; Knipscheer et al., 2009) . We replicated prelabelled pICL in the 11 presence and absence of hHSF2BP and measured the decline of the X-shape structures in 12 time. No difference was observed in the presence or absence of HSF2BP indicating that ICL 13 unhooking was not affected by the addition of HSF2BP [ Fig 4A] . 14 After ICL unhooking a nucleotide is inserted across from the unhooked adduct by a currently 15 unknown polymerase, followed by strand extension mediated by REV1 and polymerase z.
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This translesion synthesis (TLS) process can be monitored by separating nascently labelled 17 pICL replication products that are linearized by digestion with HincII on a denaturing agarose 18 gel. Replication stalling at the ICL site will initially generate arm fragments and these will be 19 converted to fully extended linear fragments by TLS [ Fig S4C] . Later, HR will result in the 20 accumulation of additional full-length linear fragments that are cleavable by SapI. Of note, 21 the TLS products are not cleavable by SapI because the unhooked adduct is not removed in 22 Xenopus egg extract (Räschle et al., 2008) . We separated HincII-digested nascent labelled 23 repair products, that were replicated in the presence and absence of hHSF2BP, on a 24 denaturing agarose gel and quantified the accumulation of linear products [ Fig S4D] . While 25 linear products accumulated in both conditions, the increase was less in the presence of 26 HSF2BP [ Fig 4B] . This could be caused by a defect in TLS and/or a defect in HR. To address 27 this, we digested the repair intermediates with both HincII and SapI and performed the 28 same analysis. The accumulation of full-length linear products was similar in absence or 29 presence of HSF2BP [ Fig 4B] . This shows that TLS is not affected by the addition of HSF2BP, 30 9 and suggests that the reduction of linear products is caused by a defect in HR. To address 1 this directly, repair intermediates were linearized and analyzed by two-dimensional gel 2 electrophoresis (2DGE). In the absence of hHSF2BP, an X-arc was formed indicating the 3 presence of HR intermediates (Long et al., 2011) . In contrast, the presence of hHSF2BP but 4 not its R200T mutant inhibited the formation of the X-arc [ Fig 4C, S4E] , providing further 5 evidence that HR is affected by HSF2BP. 6 HSF2BP reduces loading of RAD51 and BRCA2 to ICLs 7 To address how HSF2BP inhibits HR during ICL repair we investigated BRCA2 and RAD51 8 recruitment to damage. To this end, we pulled down the pICL plasmid DNA during ICL repair 9 in Xenopus egg extract using streptavidin beads coated with biotinylated LacI protein, which 10 binds efficiently to nonspecific DNA (Budzowska et al., 2015) . While this assay was not 11 sensitive enough to detect BRCA2, RAD51 was readily accumulated on pICL in the absence 12 of hHSF2BP [ Fig 4D] . In contrast, no RAD51 was detected on pull downs in the presence of 13 hHSF2BP [ Fig 4D] . Consistent with this, RAD51 accumulation at sites of MMC-induced 14 damage in human cells was significantly inhibited by HSF2BP [ Fig 4E] . To investigate the 15 binding of BRCA2 to the damaged DNA we then used chromatin immunoprecipitations 16 (ChIP). BRCA2 was immunoprecipitated from ICL repair reactions in the presence and 17 absence of HSF2BP, and the co-precipitated DNA was amplified by quantitative PCR with 18 primers specific to the ICL region. BRCA2 accumulated at the ICL during repair as previously 19 described (Long et al., 2014) . In the presence of HSF2BP the accumulation of BRCA2 at the 20 site of damage was reduced and the protein was unloaded earlier compared to conditions Our study describes a novel, specific and evolutionarily highly conserved direct interaction 4 between BRCA2, the key mediator of HR in vertebrates, and a previously functionally 5 uncharacterized protein HSF2BP. We mapped the interaction to a short region within 6 BRCA2, which despite its high sequence conservation had no described function. While a 7 physiological role for HSF2BP may be restricted to germline, our work demonstrates the 8 consequences of its ectopic activation. Using cell-biological methods in somatic human cells 9 and biochemical assays in Xenopus laevis egg extracts we show that the presence of HSF2BP neither is the recruitment of the factors involved in these steps. Second, the formation of 18 HR intermediates is inhibited upon addition of HSF2BP. Third, RAD51 loading onto ICL 19 containing plasmids is abrogated by HSF2BP. These data are also consistent with our finding 20 that cells overproducing HSF2BP are sensitive to cisplatin and MMC, and show reduced 21 RAD51 focus formation. How does HSF2BP affect HR? Several lines of evidence, including 22 single particle tracking data, indicate that BRCA2 and HSF2BP form a stable complex in cells. 23 ChIP analysis in Xenopus egg extracts indicate that this complex is recruited to ICLs during 24 repair. In this complex, HSF2BP could affect RAD51 loading by a direct inhibition of BRCA2 25 function and/or an alteration in loading kinetics of BRCA2 onto the damage. In support of 26 the latter, we showed reduced ICL recruitment and premature unloading of BRCA2 in the 27 presence of HSF2BP. In fact, unloading precedes the formation of HR intermediates as 28 observed on 2DGE. After 90 minutes no HR intermediates were visible but BRCA2 has 29 already been completely unloaded in presence of HSF2BP. How HSF2BP promotes early 30 unloading of BRCA2 is currently not known but this could involve regulated degradation or 1 posttranslational modification. In addition, HSF2BP could inhibit BRCA2 function directly by 2 preventing it from interacting with an important cofactor, or by affecting essential structural 3 rearrangements. Why these mechanism specifically compromises HR during ICL repair, and 4 not general HR, requires further investigation. 5 The sensitivity to ICL inducing agents and PARPi caused by ectopic HSF2BP expression, which 6 is similar to FA protein deficiency, has an important implication, namely that the molecular (Epstein, 2009; Jaenisch and Bird, 2003; Lee and Young, 2013; Prelich, 2012) . It is Based on HSF2BP expression profile and the phenotypes we described, it does not seem 28 likely that mutations in the HBD would predispose to cancer by disrupting the HSF2BP-29 BRCA2 interaction. On the contrary, such mutation would be protective against genomic 30 instability induced by HSF2BP. On the other hand, since we show that HSF2BP binding to 1 HBD is required for ICL repair disruption, it is plausible that HBD itself is involved in a 2 molecular transaction required for ICL repair, which is blocked by HSF2BP. In this case, 3 missense mutations in HBD could be pathogenic. We surveyed several curated databases 4 combining clinical, functional and sequence data on BRCA2 (Béroud et al., 2016; Fokkema et 5 al., 2011; Szabo et al., 2000) and found two experimentally characterized variants (R2336H 6 and I2285V). The R2336H variant is classified as potentially deleterious or causal, based on 7 cellular HR assay, but its effect is attributed to aberrant splicing and BRCA2 protein and no breast cancer predisposition was found among c.6853A>G carriers, which led to the 16 conclusion that increase in ∆12 spice variant in breast cancer cell lines is an epiphenomenon 17 (Li et al., 2009 ). However, it is tempting to speculate, based on our findings, that HSF2BP 18 overexpression followed by shift to BRCA2∆12 could be beneficial for cancer cell evolution, 19 by first inducing genomic instability leading to transformation, and then reverting back to 20 the more efficient DNA repair for robust proliferation. The ratio between BRCA2 splice 21 variants may explain potential differences in sensitization due to HSF2BP overproduction in (Stoepker et al., 2015) . However, PARPi sensitivity of core FA proteins 31 and I/D2 is much lower than in BRCA2-deficient cells, and lack of sensitivity was concluded 1 for FA-A, -L, -D2, -I, -J patient lines (Kim et al., 2013) . To the extent a comparison between 2 disparate cell lines can be made, sensitization by HSF2BP overproduction is closer to PARPi 3 sensitivity of core FA and FA-D2/I cells than to the much more severe sensitivity of cells 4 deficient in general HR (BRCA2, PALB2, RAD51, BRCA1) or FANCP/SLX4. This is consistent 5 with an inhibitory role for HSF2BP in HR during ICL repair but not in general HR. 6 Our data demonstrate that ectopic (over)expression of HSF2BP can cause genomic 7 instability specifically due to inefficient ICL repair, while other HR reactions remain 8 unaffected: cells proliferate normally and the steps preceding HR intermediate formation in 9 Xenopus egg extract, all of which are replication-dependent, are also unaffected. This 10 specificity is important for two reasons. First, it is emerging that accumulation of genomic 11 instability due to gradual segmental loss of the BRCA2 function is likely to be more 12 conducive to oncogenic transformation than the catastrophic consequences of the complete 13 inactivation of this essential gene (Feng and Jasin, 2018; Hartford et al., 2016; Tan et al., 14 2017 ). Second, we anticipate that the separation of general and ICL-specific HR functions of 15 BRCA2, which we could achieve in cultured cells and in biochemical assays, will be as useful 16 for understanding the complex biology of BRCA2 as was the separation of its DSB repair and 17 of replication fork stabilization functions (Lomonosov et al., 2003; Schlacher et al., 2012) . 18 Finally, this novel mechanism of ICL repair inhibition could be used to for the development 19 of more efficient treatment for cancer patients with interstrand crosslinking agents. With the exception of U2OS GFP-HSF2BP clone #5, all stable cell lines were constructed 1 using PiggyBac vectors by co-transfecting them with the transposase expression construct 2 (mPB or hyPBase), followed by selection with either 1.5 µg/ml puromycin or 800 µg/ml 3 G418 was started and maintained for 6-10 days. Stable transformation was highly efficient 4 (>95% GPF+ cells when GFP-tagged constructs were used) and therefore clonal isolation was 5 not performed. Stable line U2OS GFP-HSF2BP clone #5 used in the initial experiment was 6 constructed by random integration of pEGPFN1-HSF2BP construct with 800 µg/ml G418 7 selection. Several GFP+ individual clones were isolated, expanded and checked for uniform 8 expression of single major GPF-fused protein by FACS and immunoblotting. shRNA expression constructs were obtained from the Sigma mission library (TRC 1.5). 19 Lentiviral packaging plasmids (pMDLg/pRRE, pRSV-REV and pMD2.G) and shRNA expression 20 constructs were transfected into HEK293T cells using calcium phosphate precipitation. 24h 21 after transfection the medium was changed and 48 h after transfection the supernatant of 22 the HEK293T cells was added to U2OS cells. This process was repeated the next day. Forty-23 eight hours after the second transduction, selection with 1.5 µg/ml puromycin was started. 24 Two of the five tested shRNAs efficiently reduced the concentration of overproduced GFP- (Chalkley and Verrijzer, 2004) . Antibodies against xlREV1, xlXPF, and xlFANCD2 were 20 previously described (Budzowska et al., 2015; Klein Douwel et al., 2014; Räschle et al., 2008; 21 Walter & Newport, 2000). The BRCA2 antibody was raised against residues 1842-2080 of 22 xlBRCA2. The cDNA encoding the fragment was codon-optimized for E. coli, synthesized 23 (gBlocks Gene Fragments, Integrated DNA Technologies), and ligated into the XhoI-BamHI 24 sites of the pETDuet-1 vector (Novagen). The fragment was overexpressed in E. coli 25 BL21(DE3) cells (New England BioLabs) with a N-terminal His-tag, and purified by the 26 method described previously (Klein Douwel et al., 2014) . The purified antigen was used for 27 immunization of rabbits (PRF&L, Canadensis, USA). Specificity of the antisera was confirmed 28 using western blotting. 29 Immunoblotting and Cell fractionation 1 To prepare total protein lysates, cells were scraped in PBS and lysed in 2x Laemmli SDS 2 loading buffer (120 mM Tris pH 6.8, 4% SDS, 10% Glycerol), after determining the protein 3 concentration in the lysate by Lowry method, the lysate was complemented by 10x reducing 4 additive (0.1% bromophenol blue, 0.5% β-mercaptoethanol). For fractionation 1 million cells 5 were collected by trypsinization, washed with ice-cold PBS, re-suspended in Schaffner's lysis 6 buffer (10 mM HEPES-NaOH pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 7 protease inhibitor cocktail); after 15-min incubation on ice NP-40 was added to the final 8 concentration 0.1% and solution was vortexed. Nuclei were pelleted by 30 sec 9 centrifugation at 18,000 rcf, re-suspended by shaking for 15 min at 4 °C in nuclear extraction 10 buffer (20 mM HEPES-NaOH pH 7.9, 400 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 11 protease inhibitor cocktail) and centrifuged for 5 min at 18,000 rcf to separate chromatin 12 pellet from soluble nucleoplasmic fraction; the pellet was re-suspended in Laemmli SDS 13 loading buffer. Proteins were separated on polyacrylamide handcast tris-glycine, or precast 14 bis-tris or tris-acetate gels (Novex) and blotted on nitrocellulose or PVDF. For BRCA2 15 detection 4-8% precast tris-acetate gels were used, and transfer was performed in 2x 16 Towbin transfer buffer (50 mM Tris, 384 mM glycine, 20% methanol) at 300 mA constant 17 current for 2h at 4 °C to PVDF membrane. Membranes were blocked in 3% milk in 18 PBS+0.05% Tween. After overnight incubation with the primary antibody, membranes were 19 washed in PBS+0.05% Tween and incubated with horseradish peroxidase-conjugated 20 secondary antibodies (Jackson Immunoreserach). Blots were developed using homemade 21 ECL reagents and detected with the Alliance 4.7 (UVItec). 22 Protein Purification 23 Human HSF2BP cDNA was re-cloned into pETM11 (6xHis-TEV) expression vector using 24 Gibson assembly and transformed into E. coli Rosetta2 (DE3) pLysS. A starter culture (LB + 25 50 µg/ml kanamycin, 30 µg/ml chloramphenicol) was grown overnight at 37 °C, used to 26 inoculate 4.5 L of LB which was grown at 37 °C until the OD600 reached 0.6. Expression was 27 induced by addition of IPTG to 0.2 mM, incubation was continued at 16 °C for 16 h, cells 28 were harvested and frozen, thawed in equal volume of 2x lysis buffer (1M NaCl, 25mM Tris 29 pH7.5, 5% Glycerol, 5 mM β-mercaptoethanol, 1x EDTA-free protein inhibitor cocktail 30 20 (Roche)) and sonicated (8x 30 sec). The lysate was cleared by centrifugation at 35,000 rcf for 1 45 min, and loaded on Ni-NTA beads equilibrated with binding buffer (500 mM NaCl, 25mM 2 Tris pH7.5, 5% Glycerol, 5 mM β-mercaptoethanol). Beads were washed with increasing Xenopus egg extracts, DNA replication, repair assay, and lesion bypass assay 24 DNA replication and preparation of Xenopus egg extracts (HSS and NPE) were performed as 25 described previously (Tutter and Walter, 2006; Walter et al., 1998) . Preparation of plasmid 26 with a site-specific cisplatin ICL (pICL), and ICL repair assays were performed as described 27 (Enoiu et al., 2012; Räschle et al., 2008) . Briefly, pICL (9 ng/µL) and pQuant (0.45 ng/µL) 28 were first incubated in a high-speed supernatant (HSS) of egg cytoplasm for 20 min at ~ 20 1 °C, which promotes the assembly of prereplication complexes on the DNA. Addition of two 2 volumes nucleoplasmic egg extract (NPE), which also contained 32 P-α-dCTP, triggers a single 3 round of DNA replication. Where indicated, his-tagged hHSF2BP (0.45 µM) or his-tagged 4 xlHSF2BP (0.45 µM) was added to NPE prior to mixing with HSS. Aliquots of replication 5 reaction (3.8 µl) were stopped at various times with 45 µl Stop solution II (50 mM Tris pH 6 7.5, 0.5% SDS, and 10 mM EDTA,). Samples were incubated with RNase (0.13 µg/µl) for 30 7 min at 37 °C followed by proteinase K (0.5 µg/µL) overnight at room temperature. DNA was 8 extracted using phenol/chloroform, ethanol-precipitated in the presence of glycogen (30 9 mg/ml), and resuspended in 3.8 μl TE (10 mM Tris pH 7.5 and 1 mM EDTA). ICL repair was 10 analyzed by digesting 1 μl extracted DNA with HincII, or HincII and SapI, separation on a 11 0.8% agarose gel in 1x TBE buffer, and quantification using Typhoon TRIO+ (GE Healthcare) 12 and ImageQuant TL software (GE Healthcare). Repair efficiency was calculated as described 13 (Knipscheer et al., 2012) . For lesion bypass assay, the digested DNA was ethanol-14 precipitated, and resuspended in 12 µL alkaline loading buffer (50 mM NaOH, 1 mM EDTA, 15 and 2.5 % Ficoll-400). Fragments were then separated on a 0.8% agarose gel in alkaline 16 buffer (50 mM NaOH and 1 mM EDTA), after which the gel was dried on Amersham Hybond-17 XL membrane (GE Healthcare) and exposed to a phosphor screen. The band intensity of the 18 bypassed product was quantified with Typhoon TRIO+ using ImageQuant TL software. The 19 highest value was set at 100% for the bypassed product. with DAPI or immunostained with anti-53BP1 antibody. 29 Oblique illumination microscopy and particle tracking were performed exactly as described 1 (Reuter et al., 2014) . The experiment was repeated three times, two independent 2 Hsf2bp GFP/+ clones were used in each. 3 HeLa and U2OS cells were treated overnight with 100 nM MMC, pre-extracted before 4 fixation for 1 min in Triton X-100 buffer (0.5% Triton X-100, 20 mM HEPES-KOH pH 7.9, 50 5 mM NaCl, 3 mM MgCl2, 300 mM sucrose), fixed in 2% paraformaldehyde in PBS and stained Incision assay was performed as described previously (Klein Douwel et al., 2014; 2017) . 12 Briefly, pICL (225 ng) and pQuant (11.3 ng) were incubated with 1.5 units NB-BSR DI enzyme 13 (NEB) in 1× NEBuffer 2.1 for 30 min at room temperature. Subsequently, the nick translation were separated on a 0.8% denaturing agarose gel in alkaline buffer, after which the gel was 22 dried on Amersham Hybond-XL membrane and exposed to a phosphor screen. The band 23 intensity of the X-shape structure was measured with Typhoon TRIO+ and quantified using 24 ImageQuant TL software. The highest value was set at 100% for the X-shape structure. 25 Two-dimensional gel electrophoresis (2DGE) 26 2DGE was performed as described previously (Long et al., 2011) . Replication samples of pICL 27 at various times were extracted and digested with HincII. Fragments were then analyzed by 28 2DGE. The first-dimension gel consisted of 0.4% agarose run in 0.5x TBE buffer at 0.86 V/cm 29 for 24 h at room temperature. The lanes of interest were cut out, casted across the top of 1 the second-dimension gel consisting of 1% agarose with 0.3 μg/ml ethidium bromide, and 2 run in 0.5x TBE containing 0.3 μg/ml ethidium bromide with buffer circulation at 3.5 V/cm 3 for 14.5 h at room temperature. The gel was dried on Amersham Hybond-XL membrane and 4 exposed to a phosphor screen. DNA was visualized using a Typhoon TRIO+. 18 Cell 152, 1237 Cell 152, -1251 Li, L., Biswas, K., Habib, L.A., Kuznetsov, S.G., Hamel, N., Kirchhoff, T., Wong, N., Armel, S., 20 Chong, G., Narod, S. A., et al. (2009) . Functional redundancy of exon 12 of BRCA2 revealed by 21 a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Hum Mutat 30, 1543 Mutat 30, -1550 Lombardi, A.J., Hoskins, E.E., Foglesong, G.D., Wikenheiser-Brokamp, K.A., Wiesmüller, L., 23 Hanenberg, H., Andreassen, P.R., Jacobs, A.J., Olson, S.B., Keeble, W.W., et al. (2015) . 24 Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in 25 Fanconi Anemia Head and Neck Cancers. Clin Cancer Res 21, 1962 Res 21, -1972 Lomonosov, M., Anand, S., Sangrithi, M., Davies, R., and Venkitaraman, A.R. (2003) . 56, 174-185. 33 Martinez, J.S., Baldeyron, C., and Carreira, A. (2015) . Molding BRCA2 function through its 34 interacting partners. Cell Cycle 14, [3389] [3390] [3391] [3392] [3393] [3394] [3395] McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Bialkowska, A., Swift, S., Giavara, S., 36 O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. (2006) . Deficiency in the repair of DNA 37 damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase 1 inhibition. Cancer Research 66, [8109] [8110] [8111] [8112] [8113] [8114] [8115] Mezulis, S., Yates, C.M., Wass, M.N., Sternberg, M.J.E., and Kelley, L.A. (2015) . The Phyre2 3 web portal for protein modeling, prediction and analysis. Nat Protoc 10, 845-858. 4 Modesti, M., Budzowska, M., Baldeyron, C., Demmers, J.A.A., Ghirlando, R., and Kanaar, R. 5 (2007) . RAD51AP1 is a structure-specific DNA binding protein that stimulates joint molecule 6 formation during RAD51-mediated homologous recombination. Mol Cell 28, 468-481. I  II  II  III  IV  V  VI  VII  VIII  IX   I  II  II  III  IV  V  VI  VII  VIII I  II  II  III  IV  V  VI  IX   I  II  II  III  IV  V  VI  IX   I  II  II  III  IV  V  VI I  II  III  IV  V  VI  VII  VIII   I  II  III  IV  V  VI  VIII   I  II  III  IV  V intermediates were isolated and digested with HincII, or HincII and SapI, and separated on 10 agarose gel. Repair efficiency was calculated and plotted. As repair kinetics and absolute 11 efficiency is highly dependent on the egg extract preparation single experiment is plotted 12 here, and a replica is shown in [Fig S2J] . #, SapI fragments from contaminating uncrosslinked 13 plasmid present in varying degrees in different pICL preparations. See also [Fig S2K] . 
